Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
macular degeneration
Pharma
Bayer de-emphasizes the impact of Roche's Vabysmo on Eylea sales
Roche’s Vabysmo has taken a chunk of the market from Regeneron and Bayer’s Eylea. But Bayer hasn’t taken quite the same hit as its U.S. partner.
Kevin Dunleavy
May 14, 2024 11:46am
Dupixent COPD delay possible, Eylea down 2%, Regeneron says
May 2, 2024 12:00pm
Roche's juggernaut Vabysmo routs analyst consensus
Apr 24, 2024 11:29am
Regeneron touts 'favorable' physician reports on Eylea HD
Feb 2, 2024 11:09am
Roche's Vabysmo shows durability in retinal vein occlusion
Oct 10, 2023 10:21am
FDA approves Regeneron’s HD Eylea, triggering battle with Roche
Aug 21, 2023 11:01am